Delivery Order SPE2DR25D3404-SPE2DR26F5V8K
- Not listed
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order by the Defense Logistics Agency (DLA) on January 12, 2026, for the supply of Enbrel 50 mg/mL SureClick auto-injectors valued at $29,386.50. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be completed at the contractor's Conshohocken, Pennsylvania location by January 13, 2026. This delivery order is issued under...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $7,738.43 by the Defense Logistics Agency (DLA) on January 13, 2026, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of January 14, 2026, represents a non-set-aside competitive award and will be performed at the awardee's facility in Conshohocken, Pennsylvania. The award is issued under a larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $27,316.78 by the Defense Logistics Agency (DLA) on December 3, 2025, for the supply of ENBREL 50 mg/mL SureClick auto-injectors. This non-set-aside, firm fixed-price delivery order is scheduled for completion by December 4, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp was awarded a $11,685 firm fixed price delivery order by the Defense Logistics Agency (DLA) on October 29, 2025, for the supply of ENBREL 50 mg/ml SureClick auto-injectors. The contract, which carries no set-aside designation, was competitively awarded and is scheduled for completion by October 30, 2025. Performance will be executed from the contractor's Conshohocken, Pennsylvania facility, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $39,057.22 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of July 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $105,657.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of October 28, 2025. This non-set-aside, competitively awarded contract represents a single delivery order fulfillment under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of...
- AmerisourceBergen Drug Corp was awarded a $67,062.44 firm fixed-price delivery order by the Defense Logistics Agency's Medical Supply Chain on September 26, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injector pens. The contract, which is a child award under a larger indefinite delivery contract vehicle, carries an ultimate completion date of September 29, 2025, and was competitively awarded with no set-aside designation. Performance will be executed from the company's corporate...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $36,635.32 by the Defense Logistics Agency on January 13, 2026, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 14, 2026. The delivery order is issued under Amerisourcebergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp has been awarded a delivery order for ENBREL 50 mg/ml SureClick auto-injectors valued at $24,517.71 by the Defense Logistics Agency's Medical Supply Chain, with an ultimate completion date of September 9, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ENBREL (etanercept) is a TNF inhibitor used to treat...
- SPE2DR25D3404Indefinite Delivery Contract
- SPE2DR25D3404-SPE2DR26F5V8KDelivery Order
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $48,265.02 by the Defense Logistics Agency (DLA) on January 20, 2026, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. This firm fixed-price delivery order, which is not subject to any set-aside designation, represents a competitively awarded transaction under the company's broader pharmaceutical supply relationship with the federal government. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of January 21, 2026. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at up to $999,999,999.00 and extending through December 2026. The IDC serves as a critical vehicle for supplying a wide range of pharmaceutical products, medical supplies, and specialty medications to support military healthcare systems globally. ENBREL, a biologic medication used primarily for rheumatoid arthritis and other inflammatory conditions, represents the type of specialized therapeutic product that DLA procures through this contract vehicle to support military treatment facilities and veterans' healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.3k | 1/19/26 |